News
WinRevair’s Phase 3 HYPERION trial was stopped early for efficacy, with positive top-line results announced in the month ...
Cash from operations— $36 million cash from operations for Q2 2025, exceeded guidance due to favorable cash collection, lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback